Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited.

about

Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited.

Item

http://www.wikidata.org/entity/Q47372560

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited.

@en

Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited.

@nl

type

Item

label

Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited.

@en

Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited.

@nl

prefLabel

Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited.

@en

Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited.

@nl

P1476

Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited.

@en

P2093

Chris Walker

http://www.w3.org/2001/XMLSchema#string

Luigi M Biasucci

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease

Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study

P304

55-71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/00325481.2018.1412799

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29202670

http://www.w3.org/2001/XMLSchema#string